Covalent Group has signed a $1.7m (€1.3m) contract with a new,
undisclosed pharma firm to carry out a Phase II trial on a new drug
for atherosclerosis - a disease affecting the arterial blood
vessels throughout the body.
As global contract research spending remains robust, business is
booming for Pharmaceutical Product Development (PPD) as the US firm
reported a surge in sales, profits and new business for its second
Researchers have published a new article launching a scathing
attack on the growing incidence of healthcare professionals being
paid exuberant 'finder's fees' whenever they recruit a patient onto
a clinical trial.
The Food and Drug Administration (FDA) will beef up its process for
disclosing the conflicts of interest of its advisory experts in a
bid to restore its reputation after a survey suggests its
scientists may be too closely tied with...
The Food and Drug Administration (FDA) has been left red-faced
after a survey recently released by the Union of Concerned
Scientists (UCS), found a "disturbing level of interference in the
A new report compiled in the wake of the drug trial scandal, which
left six men fighting for their lives, has re-iterated the call for
scientists to proceed with extreme caution when testing such drugs
in the future.
Avalon Pharmaceuticals and ChemDiv have revealed details on a
collaboration in which the two companies are to engage in drug
discovery in the oncology sector focusing on small molecules as a
basis for therapeutic development.
Outourcing-Pharma focus on: FDA clinical trial initiatives
Despite looming threats from cheap Asian competitors, European
contract research organisations (CROs) still have a fighting chance
in the global R&D outsourcing market, according to a report by
research analysts Frost & Sullivan.